TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking
Brief Summary: This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.


Options:
A: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
B: Arm Label: Recovery management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Recovery management | Intervention Type: BEHAVIORAL; Name: Recovery management; Assigned to Arm(s): Recovery management intervention
C: Arm Label: Intramuscular naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vivitrol- Intramuscular naltrexone (depot-formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vivitrol- Intramuscular naltrexone (depot-formulation); Assigned to Arm(s): Intramuscular naltrexone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Screening for intimate partner violence | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Screening for intimate partner violence; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking
Brief Summary: This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B
B: Arm Label: Intramuscular naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vivitrol- Intramuscular naltrexone (depot-formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vivitrol- Intramuscular naltrexone (depot-formulation); Assigned to Arm(s): Intramuscular naltrexone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: TAU only; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Outpatient Treatment | Arm Label: TMAC only; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling | Arm Label: TMAC plus; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling plus incentives | Intervention Type: OTHER; Name: Intensive Outpatient Treatment; Assigned to Arm(s): TAU only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling; Assigned to Arm(s): TMAC only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling plus incentives; Assigned to Arm(s): TMAC plus
D: Arm Label: Patient Noncompliance; Type: EXPERIMENTAL; Interventions: Drug: haloperidol decanoate, Drug: haloperidol, Behavioral: Customized Adherence Enhancement | Intervention Type: DRUG; Name: haloperidol decanoate; Assigned to Arm(s): Patient Noncompliance | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): Patient Noncompliance | Intervention Type: BEHAVIORAL; Name: Customized Adherence Enhancement; Assigned to Arm(s): Patient Noncompliance

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Continuous High Volume Veno-venous Hemofiltration vs. Standard Care for Post-cardiac Surgery Shock Requiring High Doses Catecholamines. The HEROICS Study: HEmofiltration to Rescue Severe shOck followIng Cardiac Surgery
Brief Summary: This study seeks to determine if early continuous High Volume Veno-venous Hemofiltration (HVHF) reduces 30-day all cause mortality in post-cardiac surgery patients developing shock requiring high doses catecholamines.


Options:
A: Arm Label: Early initiation of RRT; Type: EXPERIMENTAL; Interventions: Procedure: Renal Remplacement Therapy | Arm Label: Deferred RRT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal Remplacement Therapy | Intervention Type: PROCEDURE; Name: Renal Remplacement Therapy; Assigned to Arm(s): Deferred RRT, Early initiation of RRT
B: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
C: Arm Label: Standard RRT initiation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard RRT initiation | Arm Label: Accelerated RRT initiation; Type: EXPERIMENTAL; Interventions: Other: Accelerated RRT initiation | Intervention Type: OTHER; Name: Standard RRT initiation; Assigned to Arm(s): Standard RRT initiation | Intervention Type: OTHER; Name: Accelerated RRT initiation; Assigned to Arm(s): Accelerated RRT initiation
D: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Continuous High Volume Veno-venous Hemofiltration vs. Standard Care for Post-cardiac Surgery Shock Requiring High Doses Catecholamines. The HEROICS Study: HEmofiltration to Rescue Severe shOck followIng Cardiac Surgery
Brief Summary: This study seeks to determine if early continuous High Volume Veno-venous Hemofiltration (HVHF) reduces 30-day all cause mortality in post-cardiac surgery patients developing shock requiring high doses catecholamines.


Options:
A: Arm Label: High Volume; Type: EXPERIMENTAL; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Arm Label: Medium Volume; Type: ACTIVE_COMPARATOR; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): High Volume | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): Medium Volume
B: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care
C: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Continuous High Volume Veno-venous Hemofiltration vs. Standard Care for Post-cardiac Surgery Shock Requiring High Doses Catecholamines. The HEROICS Study: HEmofiltration to Rescue Severe shOck followIng Cardiac Surgery
Brief Summary: This study seeks to determine if early continuous High Volume Veno-venous Hemofiltration (HVHF) reduces 30-day all cause mortality in post-cardiac surgery patients developing shock requiring high doses catecholamines.


Options:
A: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care
B: Arm Label: High Volume; Type: EXPERIMENTAL; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Arm Label: Medium Volume; Type: ACTIVE_COMPARATOR; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): High Volume | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): Medium Volume
C: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
D: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Continuous High Volume Veno-venous Hemofiltration vs. Standard Care for Post-cardiac Surgery Shock Requiring High Doses Catecholamines. The HEROICS Study: HEmofiltration to Rescue Severe shOck followIng Cardiac Surgery
Brief Summary: This study seeks to determine if early continuous High Volume Veno-venous Hemofiltration (HVHF) reduces 30-day all cause mortality in post-cardiac surgery patients developing shock requiring high doses catecholamines.


Options:
A: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
B: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
C: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Collaborative Behavioral e-Care to Decrease Cardiovascular Risk (e-Compare)
Brief Summary: The e-Care for Heart Wellness study will look at ways to reduce a person's chances of getting heart disease. We are asking about 100 Group Health members whose electronic medical record shows they have uncontrolled high blood pressure to be in the study. Having high blood pressure increases your future risk of heart attacks and strokes.

There are many things you can do to help keep your heart healthy. Examples include lowering blood pressure and cholesterol, eating healthier, and being more active. Our goal is to test whether getting care and supportive emails from a dietician helps people do things like this to lower their chances of having a heart attack or a stroke.

For some people, this study will involve both research and clinical care. About half the people in the study will receive care related to heart disease prevention from a dietician. It's a standard clinical practice for dieticians to help people reduce their risk of heart attacks and strokes. What's different about this study is using emails from a dietician to help people take steps to improve their heart health.


Options:
A: Arm Label: Dietician electronic counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietician electronic support | Arm Label: Self Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietician electronic support; Assigned to Arm(s): Dietician electronic counseling
B: Arm Label: Information Support System; Type: EXPERIMENTAL; Interventions: Other: Information Support System | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Information Support System; Assigned to Arm(s): Information Support System
C: Arm Label: Case; Type: EXPERIMENTAL; Interventions: Behavioral: Peer Coach Phone Calls, Behavioral: Health Educator Visits, Other: written materials | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: written materials | Intervention Type: BEHAVIORAL; Name: Peer Coach Phone Calls; Assigned to Arm(s): Case | Intervention Type: BEHAVIORAL; Name: Health Educator Visits; Assigned to Arm(s): Case | Intervention Type: OTHER; Name: written materials; Assigned to Arm(s): Case, Control
D: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil
D: Arm Label: Monotherapy (Cytisine only); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytisine | Arm Label: Monotherapy (Nicotine e-cigarette only); Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine delivered via an e-cigarette | Arm Label: Combination therapy (Cytisine plus a nicotine e-cigarette); Type: ACTIVE_COMPARATOR; Interventions: Combination Product: Cytisine plus nicotine delivered via an e-cigarette | Intervention Type: DRUG; Name: Cytisine; Assigned to Arm(s): Monotherapy (Cytisine only) | Intervention Type: DRUG; Name: Nicotine delivered via an e-cigarette; Assigned to Arm(s): Monotherapy (Nicotine e-cigarette only) | Intervention Type: COMBINATION_PRODUCT; Name: Cytisine plus nicotine delivered via an e-cigarette; Assigned to Arm(s): Combination therapy (Cytisine plus a nicotine e-cigarette)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A
C: Arm Label: Bupropion SR; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: smoking cessation counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Behavioral: smoking cessation counseling | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: smoking cessation counseling; Assigned to Arm(s): Bupropion SR, Placebo
D: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose

Answer: A